Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair. Beam Therapeutics’ investigational base ...

Data work in 2026 asks for more than chart building. Professionals are expected to clean data, query databases, explain trends, and present findings clearly across business, finance, product, and ...

Data Analytics Training Opportunity in Python, SQL, or Spreadsheets & Dashboards Mar. 10, 2026 This unique opportunity for Nevada students to receive tuition coverage for a comprehensive Data ...

The planned closure of Bio Palette has triggered the termination of a deal that gave Beam Therapeutics rights to base editing technology. Having prepared for that outcome, Beam has retained access to ...

Beam Therapeutics expanded its liver-targeted genetic disease technology with a new program, BEAM-304, for the treatment of phenylketonuria (PKU), a disease with significant unmet need that affects ...

As Nava acquires Beam, CEO Rohan Bhobe has lofty goals: Not only to improve what the company offers to government and the public, but to improve the entire gov tech market. The move brings together ...

Few companies stand better poised than Beam Therapeutics to reap the first fruits of the FDA’s promised flexibility toward cell and gene therapies. The biotech is pioneering treatments based on base ...

Good afternoon. Thank you for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO ...

Beam has reported progress with the FDA on a potential accelerated approval path for BEAM‑302 and plans to file a Biologics License Application (BLA) for risto‑cel as early as the end of 2026. Beam ...

SACRAMENTO ― The Sacramento Kings snapped a seven-game losing streak with their 111-98 win against the Houston Rockets at Golden 1 Center on Sunday, Jan. 11. They also did something they haven't had a ...